Skip to main content
Caplight Logo









A28 Therapeutics

A28 Therapeutics

Private
La Jolla, CaliforniaHealthcare & Life Scienceshttps://a28therapeutics.com/

Last Round

Series A

Oct 30, 2023

Total Funding Raised

$1.9M

Company Overview

A28 Therapeutics is a biopharmaceutical company developing a targeted oncolytic peptide platform for the treatment of multiple cancer types.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

targeted oncolytic peptideTOP platformprecision medicineoncologypeptide therapeuticsbiopharmaceuticalcancer drug discoverydrug developmenttargeted cancer therapybiomarker assayclinical trialscompanion diagnosticssolid tumorsdrug licensingbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

A28 Therapeutics Comparables

Compare A28 Therapeutics with similar companies based on industry and business-model similarity.

A28 Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Esperance Pharmaceuticals, Inc.
88%
Cybrexa Therapeutics
79%
Shanghai Best-Link Bioscience
77%

A28 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 30, 2023

Key People

Founding team and executive leadership

Stanley T. Lewis

Founder, Chief Executive Officer

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors increased 33% MoM.

  • Nov 7, 2025

    Monthly visitors increased 166% MoM, reaching 2.1K.

A28 Therapeutics Filings

Explore SEC and related filing metadata, where available.

A28 Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about A28 Therapeutics's valuation, stock price, and market status.

Is A28 Therapeutics a public or private company?

A28 Therapeutics is a private company.

What is the current stock price of A28 Therapeutics?

A28 Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is A28 Therapeutics worth (valuation)?

Valuation information for A28 Therapeutics is not publicly available.

Can I buy A28 Therapeutics stock?

A28 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was A28 Therapeutics's last funding round?

A28 Therapeutics's most recent funding round was Series A on October 30, 2023.

Who are the main investors in A28 Therapeutics?

Investor information for A28 Therapeutics is not publicly disclosed.

Will A28 Therapeutics IPO soon?

No public IPO plans have been announced for A28 Therapeutics.

How can I track A28 Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor A28 Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLa Jolla, California
Employee Range5
Year Founded2021
Last FundingOct 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?